Vincent FERT
-
EVP Immuno-Oncology and EU Operations at Veracyte, Inc.
Veracyte
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
As an immunologist, I founded HalioDx in 2014 with my former partners at Ipsogen and Jérôme Galon, a world specialist in cancer immunology. In the summer of 2021, HalioDx joined the Veracyte group.
Veracyte implements a radically new approach to cancer diagnosis based on the analysis of the immune response: by precisely measuring the anti-tumour immune response of patients, we enable doctors to determine the severity of the disease, regardless of the cancer stage or molecular profile. Using this measurement, they should also be able to predict the response to treatment of their patients, including immunotherapies, which are at the core of the MI project.
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
#industrieHave a look on our testimonies
MI carries a strong voice for immunology research, freeing partners from their public or private sectors, breaking down disciplinary barriers and creating the essential conditions for acting together, quickly and sustainably
Emilie GARRIDO-PRADALIE
AP-HM
Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.
Jean-Paul BORG
AMU, IPC, CRCM
We have developed a library of human tumors xenografted on immunodepressed mice
Michel IOVANNA JUAN
AMU, IPC, CRCM
Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.
Daniel OLIVE
AMU, IPC, CRCM
your commitment to MI